SITC Guidelines Bundle

Immunotherapy for Prostate Carcinoma

SITC GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/953718

Contents of this Issue

Navigation

Page 7 of 7

Disclaimer This Guideline a empts to define principles of prac ce that should produce high-quality pa ent care. It is applicable to specialists, primary care providers and ancillary healthcare providers. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ul mate judgment concerning the propriety of any course of conduct must be made by the clinician a er considera on of each individual pa ent situa on. Neither IGC, SITC, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbrevia ons ADT, androgen depriva on therapy; AS, ac ve surveillance; mCRPC; metasta c castra on- resistant prostate cancer; PSA, prostate-specific an gen; RP, radical prostatectomy; RT, radia on therapy Source McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal for ImmunoTherapy of Cancer 2016;4:92. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2017 All rights reserved SITCPRO1783 Defini on of Evidence Grades Level Defini on A Strong suppor ng evidence-based data from prospec ve, randomized, controlled trials, meta-analyses, long-term follow-up of prospec ve, uncontrolled trials B Moderate suppor ng data from uncontrolled, prospec ve clinical trials C Weak suppor ng data from retrospec ve reviews and case reports Percentages Propor on of Task Force members favoring recommenda on

Articles in this issue

Links on this page

Archives of this issue

view archives of SITC Guidelines Bundle - Immunotherapy for Prostate Carcinoma